Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Tag Archives: intellectual property
Happy Birthday Patents4Life – We Are 2!
Now some of them are not yet carved in judicial stone, being at various stages of appeal, but the sum of KSR, Bilski (well, I guess it was more pro-patent than the strict M or T test it replaced with … Continue reading
Posted in About SLW
Tagged Ariad, Ariad v. Lilly, Bilski, biotechnology, biotechnology law, biotechnology news, Federal Circuit, intellectual property, ip, IP law tools, KSR, Kubin, Lilly, Myriad, Patent Law, patents, Pharmaceutical law, Prometheus v. Mayo, stem cells, Supreme Court, Warren Woessner
1 Comment
A Scheme For Maximizing The Benefits Available Under The Patent Prosecution Highway (PPH)
This post is from Mark Horsburgh of Fisher Adams Kelly in Australia. Summary File in Australia first; Request expedited examination (report issues within 3 months); Address objections and obtain acceptance; File in USA and request entry to PPH (faster and … Continue reading
Posted in Non-U.S. Practice
Tagged Australia, intellectual property, ip, IP law tools, Mark Horsburgh, Patent Law, patent strategy, patents, PPH, USPTO, Warren Woessner
Leave a comment
Centocor v. Abbott: Fed. Cir. Takes New Written Description Requirement Out For A Spin.
In an important post-Ariad decision, the Federal Circuit reversed a district court decision that Abbott’s Humira infringed claims of a Centocor patent that could have cost Abbott $1.67 billion in damages. (A copy of the decision is at the end … Continue reading